Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Abstract: Pyrrolo[2,3-b]pyridine compound for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,3-b]pyridine compound or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).

Abstract: To provide a space-saving bipolar plate for a fuel cell comprising an anode plate and a cathode plate, anode gas channels and cathode gas channels lead from main gas ports on opposite sides into an active area and are distributed across the width of said area such that they are subsequently diverted towards an opposite distribution area, and the coolant channels branch in the distribution area and, after branching, are diverted towards the anode gas channels and towards the cathode gas channels and, in each region of overlap with the anode gas channels and the cathode gas channels, are diverted collectively such that the coolant channels lead, together with the anode gas channels and the cathode gas channels, into the active area with no overlap and alternatingly with said anode gas channels and cathode gas channels.

Abstract: 7H-Pyrrolo[2,3-d]pyrimidine compound for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 7H-pyrrolo[2,3-d]pyrimidine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).

Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.

Abstract: Some implementations of the disclosure are directed to a method, comprising: receiving tapped data that was tapped from a controller of an industrial control system (ICS) while the controller executed first control code to control ICS devices of the ICS, the tapped data used during execution of the first control code, and the tapped data comprising input data obtained from one or more input components of the controller communicatively coupled to the ICS devices, or output data obtained from one or more output components of the controller communicatively coupled to the ICS devices; and after receiving the tapped data, executing, using at least the tapped data, second control code that provides an emulation of the controller, the emulation comprising running, using at least the tapped data, a process of the first control code at a faster rate than it is run by the controller executing the first control code.

Abstract: Provided are CD3 binding molecules that specifically bind to CD3, for example monospecific binding molecules that specifically bind to CD3 and multispecific binding molecules (MBMs) that specifically bind to CD3 and a tumor-associated antigen, conjugates comprising the CD3 binding molecules, and pharmaceutical compositions comprising the CD3 binding molecules and conjugates. Provided are methods of using the CD3 binding molecules, conjugates, and pharmaceutical compositions to activate T cells in a subject, for example a subject having a cancer or autoimmune disease. Provided are recombinant host cells engineered to express the CD3 binding molecules and methods of producing the CD3 binding molecules by culturing the host cells under conditions in which the CD3 binding molecules are expressed.

Abstract: A computer-implemented method for providing a system-specific secret to a computing system having a plurality of computing components is disclosed. The method includes storing permanently a component-specific import key as part of a computing component and storing the component-specific import key in a manufacturing-side storage system. Upon a request for the system-specific secret for a computing system, the method includes identifying the computing component comprised in the computing system, retrieving a record relating to the identified computing component, determining the system-specific secret protected by a hardware security module and determining a system-specific auxiliary key. Furthermore, the method includes encrypting the system-specific auxiliary key with the retrieved component-specific import key, thereby creating a auxiliary key bundle, encrypting the system-specific secret and storing the auxiliary key bundle and a system record in a storage medium of the computing system.

Abstract: Some implementations of the disclosure are directed to tapping input/output (I/O) data from an industrial control system (ICS) or applying the tapped I/O data to a learned model to perform predictive or prescriptive maintenance. In one implementation, a method comprises: tapping I/O data from a controller of an ICS while the controller executes first control code to control one or more devices of the ICS; transmitting the tapped I/O data over a network to a second system; and executing, via the second system, second control code comprising an original or modified version of all or a subset of the first control code of the ICS, wherein the second control code executes in response to receiving the tapped I/O data. The output of executing the second control code may be provided to a model to predict a future event involving the ICS or to prescribe maintenance of the ICS.

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Abstract: The present disclosure provides multispecific binding molecules that specifically bind to BCMA, a component of a human T-cell receptor complex and either CD2 or a tumor associated antigen, conjugates comprising the multispecific binding molecules, and pharmaceutical compositions comprising the multispecific binding molecules and the conjugates The disclosure further provides methods of using the multispecific binding molecules to treat disease and disorders associated with expression of BCMA. The disclosure yet further provides recombinant host cells engineered to express the multispecific binding molecules and methods of producing the multispecific binding molecules by culturing the host cells under conditions in which the multispecific binding molecules are expressed.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: In general, systems, methods, and devices for electrosurgical devices with monopolar and bipolar functionality are provided. In an exemplary embodiment, a surgical device can have bipolar functionality, in which tissue engaged by the device is treated in a bipolar energy delivery mode, and can have monopolar functionality in which tissue engaged by the device is treated in a monopolar energy delivery mode.

Abstract: A patch includes a pad with a back surface for attaching to a patient's body and with a front surface that is on an opposite side of the back surface. The patch includes a shoe coupled to the front surface and defining an internal cavity shaped to receive a monitor. The shoe includes or defines a sensory feedback feature configured to engage with the monitor. An electrical connector is positioned within the internal cavity and is configured to mechanically and electrically couple to the monitor.

Abstract: Executing a query in a disaggregated cluster. A query is received at the disaggregated cluster. A query graph is created based on the query that identifies a hierarchy of vertices, where each vertex is associated with a set of data responsive to at least a portion of the query. The compute nodes process the query graph by first identifying a minimum set of tables, files, and objects stored on the storage nodes required to retrieve data that satisfy the query. Next, the compute nodes selectively assign the identified tables, files, and objects to a leaf vertex of the query graph to optimize retrieving data from the storage nodes. Thereafter, the compute nodes process the retrieved data sets associated with each vertex using separate threads of execution for each vertex of the query graph such that leaf vertices are performed in parallel. The compute nodes then provide a result set.

Abstract: Examples are disclosed that relate to display devices and mounting brackets for securing a bezel to a display device. In one example, a display device comprises a display unit and a bezel comprising at least one pocket. The display device comprises a mounting bracket comprising a display unit attachment portion affixed to the display unit and at least one tongue that extends at least partially into the at least one pocket. Adhesive binds the at least one tongue to at least one surface of the at least one pocket, thereby coupling the bezel to the display unit via the mounting bracket.

Abstract: Executing a query in a disaggregated cluster. A query is received at the disaggregated cluster. A query graph is created based on the query that identifies a hierarchy of vertices, where each vertex is associated with a set of data responsive to at least a portion of the query. The compute nodes process the query graph by first identifying all tables, files, and objects stored on the storage nodes whose access is required to retrieve data that satisfy the query. Next, the compute nodes selectively assign the identified tables, files, and objects to a leaf vertex of the query graph to optimize retrieving data from the storage nodes. Thereafter, the compute nodes process the retrieved data sets associated with each vertex using separate threads of execution for each vertex of the query graph such that leaf vertices are performed in parallel. The compute nodes then provide a result set.

Abstract: Examples are disclosed that relate to display devices and mounting brackets for securing a bezel to a display device. In one example, a display device comprises a display unit and a bezel comprising at least one pocket. The display device comprises a mounting bracket comprising a display unit attachment portion affixed to the display unit and at least one tongue that extends at least partially into the at least one pocket. Adhesive binds the at least one tongue to at least one surface of the at least one pocket, thereby coupling the bezel to the display unit via the mounting bracket.